Clopidogrel Market Insights, Forecast, Growth, and Trends 2024-2033

"The new report published by The Business Research Company, titled Clopidogrel Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the clopidogrel market size has grown rapidly in recent years. It will grow from $10.76 billion in 2023 to $11.87 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The clopidogrel market size is expected to see rapid growth in the next few years. It will grow to $17.78 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=16376&type=smp

Rising Cardiovascular Disease Cases Fueling Growth In Clopidogrel Market
The rising cardiovascular disease is expected to propel the growth of the clopidogrel market going forward. Cardiovascular diseases refer to a range of conditions that affect the heart's structure or function, leading to impaired blood flow, abnormal heart rhythms, or other cardiovascular complications. The rising cardiovascular diseases are due to population growth and aging, lifestyle factors, stress and inactivity, healthcare system challenges, and genetic and environmental factors. Clopidogrel helps prevent cardiovascular diseases by inhibiting platelet aggregation, reducing the risk of clot formation. It is particularly beneficial in managing acute coronary syndromes, post-PCI care, stroke prevention, and peripheral arterial disease. For instance, in May 2022, according to the Centers for Disease Control and Prevention, a US-based governmental organization, the prevalence of coronary heart disease among adults aged 18 and over stood at 4.6% in 2020, experiencing a slight uptick to 4.9% in 2021. Therefore, increasing heart disease is driving the growth of the clopidogrel market.

Driving Growth The Rising Prevalence Of Peripheral Artery Diseases Fuels The Clopidogrel Market

The increasing prevalence of peripheral artery diseases is expected to propel the growth of the clopidogrel market going forward. Peripheral artery disease (PAD) is a circulatory condition characterized by the narrowing or blockage of arteries outside the heart and brain. The increasing prevalence of peripheral artery diseases is due to smoking, the aging population, hypertension, and diabetes. Clopidogrel is crucial in managing peripheral artery disease by inhibiting platelet aggregation and reducing the risk of blood clot formation. It leads to improved circulation, reduced symptoms of PAD, and a lower risk of severe complications such as acute limb ischemia and cardiovascular events. For instance, in July 2023, according to the Society For Cardiovascular Angiography And Interventions, a US-based organization, PAD affects 8-10 million Americans each year, and it is estimated that 19 million Americans will have PAD by 2050. Therefore, the increasing prevalence of peripheral artery diseases drives the clopidogrel market.

Companies Revolutionize Clopidogrel Market With Enhanced Therapies And Personalized Medicine
Major companies operating in the clopidogrel market are focused on developing innovative drugs such as Plavix (clopidogrel) to improve efficacy, reduce adverse effects, enhance patient compliance, and address the issue of clopidogrel resistance. Plavix (clopidogrel) is a vital medication in preventing and managing thrombotic cardiovascular events that inhibits platelet aggregation. It reduces the risk of heart attacks, strokes, and other clot-related complications in high-risk patients. For instance, in February 2021, Sanofi S.A., a France-based pharmaceutical company, launched Plavix (clopidogrel), which the European Commission approved. This new indication allows for the use of Plavix in combination with aspirin for 21 days, followed by long-term single antiplatelet therapy, in patients who have experienced a moderate to high-risk TIA (ABCD2 score ≥4) or minor Ischemic Stroke (NIHSS ≤3) within 24 hours of the event. Plavix is an antiplatelet medication that prevents platelets in the blood from clumping together and forming clots.

The clopidogrel market covered in this report is segmented -

1) By Type: 25Mg, 75Mg, 300Mg
2) By Sales Channel: Direct Sale, Indirect Sale
3) By Application: Hospitals, Private Clinics, Retail Pharmacies, Online Pharmacies, Other Applications
4) By End-User: Heart Attack And Strokes, Peripheral Vascular Disease, Coronary Artery Disease, Cerebrovascular Disease, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=16376&type=discount

Major companies operating in the clopidogrel market are Johnson & Johnson , F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi SA, Novartis AG, AstraZeneca Plc, Bristol-Myers Squibb , GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly & Company, Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals GmbH, Cipla Inc., Apotex Inc., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Lupin Limited, Glenmark Pharmaceuticals, Zydus Cadila Healthcare Ltd., Alkem Laboratories Ltd.

Contents of the report:
1. Executive Summary
2. Clopidogrel Market Report Structure
3. Clopidogrel Market Trends And Strategies
4. Clopidogrel Market - Macro Economic Scenario
5. Clopidogrel Market Size And Growth
…..
27. Clopidogrel Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/clopidogrel-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

"Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide."

This release was published on openPR.